Every Form 4 that Sonoma Pharmaceuticals, Inc. (SNOA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNOA filings page.
Sonoma Pharmaceuticals, Inc. director Philippe Weigerstorfer received a grant of stock options for 10,000 shares of common stock at an exercise price of $1.2600 per share. The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control. Following this award, he holds 30,001 stock options directly, expiring on July 9, 2036, as compensation for his Board service.
Trombly Amy Moss reported acquisition or exercise transactions in this Form 4 filing.
Sonoma Pharmaceuticals, Inc. reported that Chief Executive Officer Amy Moss Trombly received a grant of 10,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest on the third anniversary of the grant date or upon a change of control. Following this award, she holds 52,185 RSUs directly.
Sonoma Pharmaceuticals, Inc. director John McLaughlin received a grant of stock options for 10,000 shares of common stock at an exercise price of $1.26 per share. The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control. Following this award, he holds stock options covering 30,001 shares directly.
Sonoma Pharmaceuticals director Vanessa Jacoby received a grant of stock options. She was awarded options to acquire 10,000 shares of common stock at an exercise price of $1.26 per share for Board service. The options vest one-third each on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control, and expire on July 9, 2036. Following this grant, she holds 20,000 derivative option shares in total.
DVONCH JEROME J reported acquisition or exercise transactions in this Form 4 filing.
Sonoma Pharmaceuticals, Inc. reported that its Chief Financial Officer, Jerome J. Dvonch, received a grant of 10,000 Restricted Stock Units representing contingent rights to an equal number of common shares. Following this award, he holds 44,391 shares-related units directly. Footnotes state each RSU equals one share of common stock and reference the third anniversary of the grant date or a change of control.
Dal Poggetto John reported acquisition or exercise transactions in this Form 4 filing.
Sonoma Pharmaceuticals, Inc. reported that Controller John Dal Poggetto received a grant of 7,500 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock. The RSUs vest on the third anniversary of the grant date or upon a change of control. Following this award, Dal Poggetto holds 32,750 RSUs directly, with no shares bought or sold in the market as part of this filing.
Sonoma Pharmaceuticals director granted new stock options
A director of Sonoma Pharmaceuticals, Inc. received a stock option grant covering 10,000 shares of common stock on 01/02/2026 at an exercise price of $3.68 per share. These options vest in three equal parts on 01/02/2027, 01/02/2028, and 01/02/2029, or earlier upon a change of control, and expire on 01/02/2036. After this grant, the director beneficially owns 20,001 derivative securities, held directly, as compensation for Board service under the company’s annual stock option program.
Sonoma Pharmaceuticals disclosed that Chief Executive Officer Amy Trombly received an equity grant in the form of restricted stock units (RSUs). On 01/02/2026, she was awarded 10,000 RSUs, each representing a contingent right to receive one share of Sonoma common stock. The RSUs vest on the third anniversary of the grant date, or earlier upon a change of control, aligning the CEO’s compensation with longer-term company performance. Following this grant, Ms. Trombly beneficially owns 42,185 derivative securities related to Sonoma stock in direct ownership.
Sonoma Pharmaceuticals, Inc. filed a report showing an equity award to one of its officers. On 01/02/2026, Controller John Dal Poggetto received 5,000 restricted stock units (RSUs), each representing a contingent right to receive one share of Sonoma common stock.
The RSUs vest on the third anniversary of the grant date or upon a change of control, according to the disclosure. Following this grant, Dal Poggetto directly beneficially owns 25,250 derivative securities tied to Sonoma common stock.